Professor, Internal Medicine, Ohio State University College of Medicine
Hematology
Dr. Clara D. Bloomfield, MD
|
|
Give Review
Clara Bloomfield practices Hematology. She researched medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10/19 in Research/PrimaryCare. She received 24 awards: "Achievement", "Member", "David A. Karnofsky Memorial", "Excellence in Hematology & Oncology Research", "Henry M. Stratton Medal", "Fellow (FASCO)", "1st Annual Dr. Emil Frei III Pioneer", "Phi Kappa Phi", "ASCO Statesman", "ASCO Distinguished Service Scientific Achievement", "Distinguished Service", "Elected Member", "Expression of Appreciation", "The James Champion", "Third Human Cancer Genetics Medal", "The Best Doctors in America", "Fellow", "The Best Cancer Specialists in the U.S", "Best Doctors", "The Marion Spencer Fay", "Alpha Omega Alpha", "Phi Beta Kappa", "Whos Who in Medicine and Healthcare" and "Local Legend". Dr. Clara D. Bloomfield is a published doctor. She published 101 publications, including: 'Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL...'
Publications
- Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL...
- Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia.
- Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.
- Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, ...
- Myelodysplastic syndromes, version 2.2015.
- A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.
- Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
- Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.
- Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia witha sole trisomy 8.
- Implications of the miR-10 family in chemotherapy response of NPM1 mutated AML.
- Geoffrey Peter Herzig, MD Leukemia Pioneer (1941-2013).
- Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
- NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.
- Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808.
- GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.
- Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.
- Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients.
- A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (...
- Health Literacy Among the Amish: Measuring a Complex Concept Among a Unique Population.
- Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative S...
- Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Ac...
- Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia.
- All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129.
- Acute myeloid leukaemia in 2012: En route to improved treatment options.
- Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
- Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
- New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461.
- Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia.
- inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
- Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein upregulates expression of the anti-leukemic microRNA-181a in acute myeloid leukemia.
- The Use of Daily Aspirin, Nutritional Supplements and Alternative Medications among Amish and non-Amish living in Ohio Appalachia.
- Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia.
- Acute myeloid leukemia with adverse cytogenetic risk.
- Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
- Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (C...
- Optimal management of malignant pleural effusions (results of CALGB 30102).
- Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability.
- Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
- RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA E...
- The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
- miR-3151 interplays with its host gene BAALC and independently impacts on outcome of patients with cytogenetically normal acute myeloid leukemia.
- Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.
- Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically-abnorma...
- Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN "favorable" genetic category.
- Dietary Intake, Food Processing, and Cooking Methods Among Amish and Non-Amish Adults Living in Ohio Appalachia: Relevance to Nutritional Risk Factors for Cancer.
- High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia.
- Physical Activity Among Amish and Non-Amish Adults Living in Ohio Appalachia.
- Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
- Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetical...
- Cancer screening practices among amish and non-amish adults living in ohio appalachia.
- Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9...
- Individual patient data meta-analysis of randomized trials evaluating interleukin-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
- TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group B study.
- The prognostic and functional role of microRNAs in acute myeloid leukemia.
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
- NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.
- Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal ac...
- Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of t...
- FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogen...
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cance...
- Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
- Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
- A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
- Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression...
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
- Low cancer incidence rates in Ohio Amish.
- Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
- Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared...
- MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias.
- Acquired copy number alterations in adult acute myeloid leukemia genomes.
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
- Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myelo...
- MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
- MicroRNA expression in acute myeloid leukemia.
- Molecular signatures in acute myeloid leukemia.
- A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
- Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
- An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
- Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
- Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-ris...
- Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.
- Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Le...
- Myelodysplastic syndromes.
- Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
- Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
- DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
- Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemi...
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Canc...
- Acute myeloid leukemia. Introduction.
- Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.
- Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia gro...
- Hodgkin disease/lymphoma.
- High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients you...
- MicroRNA expression in cytogenetically normal acute myeloid leukemia.
- Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
Schools
University Of ChicagoThe Pritzker School Of Medicine
University Of Chicago Hospitals and Clinics
University Of Chicago Hospitals and ClinicsFirst Year Resident
University Of MinnesotaSecond Year Resident
University Of MinnesotaMedical Oncology Fellow
Doctors Specialties
- Internal Medicine
- Hematology
Accepted Insurances
Awards
- Achievement
- Member
- David A. Karnofsky Memorial
- Excellence in Hematology & Oncology Research
- Henry M. Stratton Medal
- Fellow (FASCO)
- 1st Annual Dr. Emil Frei III Pioneer
- Phi Kappa Phi
- ASCO Statesman
- ASCO Distinguished Service Scientific Achievement
- Distinguished Service
- Elected Member
- Expression of Appreciation
- The James Champion
- Third Human Cancer Genetics Medal
- The Best Doctors in America
- Fellow
- The Best Cancer Specialists in the U.S
- Best Doctors
- The Marion Spencer Fay
- Alpha Omega Alpha
- Phi Beta Kappa
- Whos Who in Medicine and Healthcare
- Local Legend
Education
-
University of Minnesota -
University of Chicago -
University of Chicago Pritzker School of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Jennifer R. White, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald D. Winland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley S. Park, MD |
|
Dr. David M. Powell, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Eric H. Kraut, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Abdullah H. Khan, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samir Kahwash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah A. Wall, MD |